News | January 20, 2023
Blue Jet Healthcare gets SEBI nod for IPO
The company will not receive any proceeds from the offer as all of it will go to the promoter selling shareholder.
The company will not receive any proceeds from the offer as all of it will go to the promoter selling shareholder.
Valentas and Arnipin are indicated to reduce repeated hospitalization and the risk of cardiovascular death among adult patients with chronic mild to moderate heart failure
Dolutegravir and Rilpivirine Tablets, 50 mg/25 mg, (RLD Juluca) had estimated annual sales of US $666 million in the US (IQVIA MAT September 2022)
The top 15 Indian pharma players have continued to experience anaemic growth in the US market over the five years ended FY22
The company remains committed to maintain the highest standards of compliance and will work closely with the agency to comprehensively address all the observations
APAC to see a reduction in imported surgical robotics
The cardiomyopathies market in the 68M is set to grow at a CAGR of 12.1%
This will give either party customers access enzyme expertise and assets, resulting in cost-effective, green processing for API manufacturing.
Swiftmelt 1515-I meets performance requirements and secures skin attachment
International Business is expected to post double-digit revenue growth during the quarter in constant currency.
Subscribe To Our Newsletter & Stay Updated
